Polymerase compositions, methods of making and using same
The present disclosure provides compositions, methods, kits, systems and apparatus that are useful for nucleic acid polymerization. In particular, modified polymerases and biologically active fragment thereof are provided that allow for nucleic acid amplification. In one aspect, the disclosure relates to modified polymerases useful for nucleic acid sequencing, genotyping, copy number variation analysis, paired-end sequencing and other forms of genetic analysis. In some aspects, the disclosure relates to modified polymerases useful for the generation of nucleic acid libraries or nucleic acid templates for use in various downstream processes. In some aspects, the disclosure relates to the identification of homologous amino acid mutations that can be transferred across classes or families of polymerases to provide novel polymerases with altered catalytic properties. In some aspects, the disclosure provides modified polymerases having enhanced catalytic properties as compared to a reference polymerase.
1. A composition comprising a recombinant polymerase comprising:
(a) a recombinant Bst DNA polymerase having at least 99% identity to SEQ ID NO: 20 and having at least the mutations H46R, E446Q, H572R, E220K, N234R, and D423K relative to SEQ ID NO: 1,
(b) a recombinant Klenow fragment of E. coli DNA polymerase I having at least 98% identity to SEQ ID NO: 18 and having at least the mutation D505R relative to SEQ ID NO: 18, or
(c) a recombinant Taq DNA polymerase having at least 98% identity to SEQ ID NO: 15 or SEQ ID NO: 24 and having at least one mutation comprising D732R, E745Q, or E471K relative to SEQ ID NO: 15,
wherein the recombinant polymerases of (a), (b), and (c) comprise the respective naturally occurring amino acids in each of the DNA polymerase motifs A and C.
2. The composition of claim 1 , wherein the recombinant polymerase retains polymerase activity.
3. The composition of claim 2 , wherein the polymerase activity is selected from DNA binding activity, primer extension activity, strand displacement activity, proofreading activity, nick-initiated polymerase activity, reverse transcriptase activity or nucleotide polymerization activity.
4. The composition of claim 1 , wherein, the recombinant polymerase comprises at least 99% identity to SEQ ID NO: 20 and includes one or more amino acid mutations selected from the group consisting of N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K, L212A, V241K, V251K, D264Q, D264S, D264K, Y272R, H273R, L280R, H281A, E294S, E294F, E294G, E294K, V299K, V299H, V299F, D303R, I331Q, E325R, L335T, E336P, 1354W, 1354F, I370A, Q409R, G425R, Q428W, N429R, N429K, F448K, N457T, A462T, Y477F, D480R, D480F, D480H, D480A, D480S, D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q, W577Y and D579F.
5. The composition of claim 1 , wherein the recombinant polymerase comprises at least 98% identity to SEQ ID NO: 15 and includes one or more amino acid mutations selected from the group consisting of E471K, N485R, R492K, D513K, A675K, D732R, S739W, V740R and E745Q.
6. The composition of claim 1 , wherein the recombinant polymerase comprises at least 98% identity to SEQ ID NO: 18 and includes one or more amino acid mutations selected from the group consisting of E245K, S259R, T266K, E290K, A448K, D505R, A512W, R513R and E518Q.
7. The composition of claim 1 wherein, the recombinant polymerase comprises at least 99% identity to SEQ ID NO: 20, wherein the recombinant polymerase further comprises a mutation or combination of mutations relative to SEQ ID NO: 1 selected from:
(a) H273R, H281A, H473R, Y477F, D480R, or H528A;
(b) C93 mutation;
(c) Q238 mutation;
(d) H273 mutation;
(e) H281 mutation;
(f) H473 mutation; and
(g) H528 mutation.
8. The composition of claim 7 , wherein the recombinant polymerase comprises any one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: N31, D77, D113, D114, D130, D144, L212, V241, V251, D264, Y272, H273, L280, H281, E294, V299, D303, 1331, E325, L335, E336, 1354, 1370, Q409, G425, Q428, N429, F448, N457, A462, H473, Y477, D480, N485, N487, V488, E493, M495, H528, W577 and D579.
9. The composition of claim 8 , wherein the recombinant polymerase comprises any one or more mutations relative to SEQ ID NO: 1 selected from the group consisting of: N31R, N31K, D77K, D77H, D113N, D114R, D130A, D130H, D144M, D144K, L212A, V241K, V251K, D264Q, D264S, D264K, Y272R, H273R, L280R, H281A, H281M, E294S, E294F, E294G, E294K, V299K, V299H, V299F, D303R, I331Q, E325R, L335T, E336P, 1354W, 1354F, 1370A, Q409R, G425R, Q428W, N429R, N429K, F448K, N457T, A462T, H473R, Y477F, D480R, D480F, D480H, D480A, D480S, D480N, D480Q, N485W, N485Y, N487H, N487W, N487F, N487I, V488R, E493Q, M495Q, H528A, H528R, H528K, W577Y and D579F.
10. The composition of claim 9 , wherein the recombinant polymerase retains polymerase activity.
11. The composition of claim 10 , wherein the recombinant polymerase comprises a mutation that increases dissociation time constant, increases processivity, increases accuracy, increases average read length, increases minimum read length, increases AQ20 or increase 200Q17 value as compared to a reference polymerase lacking a mutation or combination of mutations relative to the recombinant polymerase.
12. The composition of claim 1 wherein, the recombinant polymerase comprises at least at least 98% identity to SEQ ID NO: 15 or SEQ ID NO: 24, wherein the recombinant polymerase comprises a mutation or combination of mutations relative to SEQ ID NO: 15 selected from:
(a) E471K, wherein the polymerase further includes a mutation at one or more of:
N485R, R492K, D513K, A675K, D732R, S739W, V740R and E745Q;
(b) V740R, wherein the polymerase further includes a mutation at one or more of:
E471K, N485R, D513K and E745Q;
(c) an N485 mutation;
(d) an D513 mutation;
(e) an D732 mutation; and
(f) an E745 mutation.
13. The composition of claim 12 , wherein the recombinant polymerase comprises: (a) increased accuracy as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 15; (b) increased dissociation time constant as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 15; (c) increased minimum read length as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 15; (d) increased sequencing performance in the presence of a high ionic strength solution as compared to a reference polymerase lacking a mutation or combination of mutations relative to the recombinant polymerase homologous to SEQ ID NO: 15; or (e) increased average read length as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 15.
14. The composition of claim 12 , wherein the recombinant polymerase retains polymerase activity.
15. The composition of claim 12 , wherein the recombinant polymerase comprises a mutation that increases dissociation time constant, increases processivity, increases accuracy, increases average read length, increases minimum read length, increases AQ20 or increase 200Q17 value as compared to a reference polymerase lacking a mutation or combination of mutations relative to the recombinant polymerase.
16. The composition of claim 1 wherein, the recombinant polymerase comprises at least at least 98% identity to SEQ ID NO: 18, wherein the recombinant polymerase comprises a mutation or combination of mutations relative to SEQ ID NO: 18 selected from:
(a) E245K, wherein the polymerase further includes a mutation at one or more of: S259R, T266K, E290K, A448K, D505R, A512W, R513R and E518Q;
(b) D505R, wherein the polymerase further includes a mutation at one or more of:
E245K, S259R, T266K, E290K, A448K, A512W, R513R and E518Q;
(c) an E290 mutation
(d) an S259 mutation;
(e) an R513 mutation; and
(f) an A512 mutation.
17. The composition of claim 16 , wherein the recombinant polymerase comprises: (a) increased accuracy as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 18; (b) increased dissociation time constant activity as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 18; (c) increased minimum read length as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 18; (d) increased sequencing performance in the presence of high ionic strength as compared to a reference polymerase lacking a mutation or combination of mutations relative to the recombinant polymerase homologous to SEQ ID NO: 18; or (e) increased average read length as compared to a reference polymerase lacking a mutation or combination of mutations relative to SEQ ID NO: 18.
18. The composition of claim 16 , wherein the recombinant polymerase retains polymerase activity.
19. The composition of claim 16 , wherein the recombinant polymerase comprises a mutation that increases dissociation time constant, increases processivity, increases accuracy, increases average read length, increases minimum read length, increases AQ20 or increase 200Q17 value as compared to a reference polymerase lacking a mutation or combination of mutations relative to the recombinant polymerase.